What Is So Great About VBI Vaccines Inc. (VBIV)?
VBI Vaccines Inc. (NASDAQ:VBIV) has a beta value of 1.99 and has seen 3.74 million shares traded in the last trading session. The company, currently valued at $1.04B, closed the last trade at $3.94 per share which meant it lost -$0.17 on the day or -4.14% during that session. The VBIV stock price is -75.89% off its 52-week high price of $6.93 and 47.97% above the 52-week low of $2.05. If we look at the companys 10-day average daily trading volume, we find that it stood at 5.13 million shares traded. The 3-month trading volume is 3.58 million shares. The consensus among analysts is that VBI Vaccines Inc. (VBIV) is a Buy stock at the moment, with a recommendation rating of 1.20. 0 analysts rate the stock as a Sell, while 0 rate it as Overweight. 0 out of 3 have rated it as a Hold, with 3 advising it as a Buy. 0 have rated the stock as Underweight. The expected earnings per share for the stock is -$0.07. VBI Vaccines Inc. (NASDAQ:VBIV) trade information  Sporting -4.14% in the red in last session, the stock has traded in the green over the last five days, with the highest price hit on Friday, 06/11/21 when the VBIV stock price touched $3.94 or saw a rise of 5.97%. Year-to-date, VBI Vaccines Inc. shares have moved 43.27%, while the 5-day performance has seen it change 20.12%. Over the past 30 days, the shares of VBI Vaccines Inc. (NASDAQ:VBIV) have changed 37.76%. Short interest in the company has seen 35.22 million shares shorted with days to cover at 12.7. Wall Street analysts have a consensus price target for the stock at $8.00, which means that the shares value could jump 50.75% from current levels. The projected low price target is $7.00 while the price target rests at a high of $9.00. In that case, then, we find that the current price level is -128.43% off the targeted high while a plunge would see the stock gain -77.66% from current levels. VBI Vaccines Inc. (VBIV) estimates and forecasts  Figures show that VBI Vaccines Inc. shares have underperformed across the wider relevant industry. The companys shares have gained 26.28% over the past 6 months, with this year growth rate of -42.86%, compared to 8.70% for the industry. Revenue growth from the last financial year stood is estimated to be 204.40%. 3 analysts offering their estimates for the company have set an average revenue estimate of $480k for the current quarter. 3 have an estimated revenue figure of $550k for the next quarter concluding in Sep 2021. If we evaluate the companys growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was 28.90% over the past 5 years. 5 Stocks Under $10 That Are Poised to Take Off Investing in stocks under $10 could significantly increase the returns on your portfolio, especially if you pick the right stocks! Within this report you will find 5 top stocks that offer investors huge upside potential and the best bang for their buck. Investing in stocks under $10 could significantly increase the returns on your portfolio, especially if you pick the right stocks! Within this report you will find 5 top stocks that offer investors huge upside potential and the best bang for their buck. Add them to your watchlist before they take off! Get the Top 5 Stocks Now! Sponsored  VBIV Dividends  VBI Vaccines Inc. is expected to release its next earnings report in July this year, and investors are excited at the prospect of better dividends despite the companys debt issue. VBI Vaccines Inc. (NASDAQ:VBIV)s Major holders  Insiders own 3.27% of the company shares, while shares held by institutions stand at 52.98% with a share float percentage of 54.78%. Investors are also buoyed by the number of investors in a company, with VBI Vaccines Inc. having a total of 192 institutions that hold shares in the company. The top two institutional holders are Perceptive Advisors Llc with over 55.04 million shares worth more than $171.18 million. As of Mar 30, 2021, Perceptive Advisors Llc held 21.65% of shares outstanding. The other major institutional holder is State Street Corporation, with the holding of over 18.68 million shares as of Mar 30, 2021. The firms total holdings are worth over $58.1 million and represent 7.35% of shares outstanding. Also the top two Mutual Funds that are holding companys shares are SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF and iShares Russell 2000 ETF. As of Mar 30, 2021, the former fund manager holds about 6.04% shares in the company for having 15.35 million shares of worth $47.75 million while later fund manager owns 4.42 million shares of worth $13.75 million as of Mar 30, 2021, which makes it owner of about 1.74% of companys outstanding stock.